Biomarkers of ACE2 inhibition
- Funded by UK Research and Innovation (UKRI)
- Total publications:0 publications
Grant number: C19-IUC-268
Grant search
Key facts
Disease
COVID-19Funder
UK Research and Innovation (UKRI)Principal Investigator
PendingResearch Location
United KingdomLead Research Institution
MRC Metabolic Diseases UnitResearch Priority Alignment
N/A
Research Category
Clinical characterisation and management
Research Subcategory
Disease pathogenesis
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
SARS COV2 binds ACE2 to access cells, ACE2 is a key enzyme in teh breakldown of angiotensin a major stimulus to the hormone aldosterone which controls salt and potoassium homeostasis in the body. We are investigating whether this system is disturbed in COVID19 and whether this contributes to any of the cardiovascular complications of the disease